<DOC>
	<DOC>NCT00232583</DOC>
	<brief_summary>The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.</brief_summary>
	<brief_title>Preservation of Beta-cell Function in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function, as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>type 2 diabetes mellitus diagnosed within the prior 2 months HbA1c &gt; 7% at the time of inclusion willing to perform intensive diabetes management able to comply with treatment and followup regimen HbA1c &gt; 8% at time of randomization creatinine &gt; 1.5 mg/dl liver function tests &gt; 3 times the upper limit of normal severe anemia severe proliferative retinopathy NYHA class III or IV heart failure active CAD or recent (within 6 months) MI pregnant, willing to get pregnant, or not willing to practice any contraceptive method nonenglish speaking active heavy alcohol or illicit drug users (within past 6 months) history of lactic acidosis</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>TYpe 2 diabetes mellitus</keyword>
	<keyword>Newly diagnosed</keyword>
	<keyword>Beta-cell function</keyword>
</DOC>